Full-Time

Head of Computational Sciences

Posted on 10/10/2024

NewLimit

NewLimit

11-50 employees

Medicines for healthspan extension via epigenetics

Biotechnology
Healthcare

Senior, Expert

San Bruno, CA, USA

Category
Computational Biology
Genomics
Biology & Biotech
Required Skills
Data Structures & Algorithms
Requirements
  • Ph.D. in computational biology, computer science, genomics or a related field with at least 8 years experience
  • Experience building and managing high-performance computational biology teams
  • Experience designing and implementing a production data pipeline in a biotech setting
  • World-class individual contributor (has written a lot of code) in at least one of machine learning, bioinformatics, computational biology, or software engineering
Responsibilities
  • Lead, recruit, and manage a team of computational biologists, ML scientists, and software engineers.
  • Plan roadmaps and manage budgets for the Computational Sciences group.
  • Contribute to company-wide decision making.
  • Guide the development of novel algorithms and machine learning models to solve problems at the core of our business.
  • Collaborate with scientists across the company to design and interpret genomics experiments. Automate analyses to expedite our discoveries.
  • Write code. Document APIs. Commit every week. At NewLimit, everyone contributes to the execution of our plans.

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics, machine learning, and high-throughput functional assays to identify aging markers and create interventions that reverse these changes. Unlike competitors, NewLimit's approach is centered on epigenetic reprogramming, targeting age-related diseases with the goal of creating a new class of medicines that enhance the quality of life as people age. The company serves the healthcare market, working with pharmaceutical companies, healthcare providers, and individual consumers interested in anti-aging treatments.

Company Stage

Series A

Total Funding

$38.9M

Headquarters

South San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

20%

1 year growth

59%

2 year growth

105%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in epigenetic reprogramming boosts NewLimit's market potential.
  • Machine learning aids in identifying novel drug candidates for age-related diseases.
  • FDA's favorable stance on aging therapies accelerates NewLimit's market entry.

What critics are saying

  • Rapid biotech advancements could render NewLimit's technologies obsolete without continuous innovation.
  • Ethical concerns and regulatory scrutiny may delay product approvals.
  • Competition from similar biotech firms could impact NewLimit's market share.

What makes NewLimit unique

  • NewLimit focuses on epigenetic reprogramming to extend human healthspan.
  • The company uses single-cell genomics and machine learning for drug discovery.
  • NewLimit targets age-related diseases with unmet needs, like immune system and liver rejuvenation.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE